Features of modified response evaluation criteria use in solid tumors in patients with hepatocellular carcinoma
Open Access
- 9 February 2022
- journal article
- research article
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 27 (1) , 33-39
Abstract
The article reviews the key approaches to the use of modified response evaluation criteria in solid tumors (mRECIST) in patients with hepatocellular carcinoma and discusses its main strengths and features. According to the evaluation by mRECIST, complete response is defined as the disappearance of any intratumoral arterial enhancement in all target lesions. A partial response is defined as 30% decrease in the sum of the longest diameters of viable tumor target lesions compared with its baseline sum. Disease progression signifies a ≥20% increase in the sum of the longest diameters of viable tumor target lesions compared with nadir. Stable disease is defined as neither partial response nor progression.Keywords
This publication has 34 references indexed in Scilit:
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL StudyJournal of Clinical Oncology, 2013
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS StudyJournal of Clinical Oncology, 2013
- Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An updateHepatology Research, 2012
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- Surgical management of hepatocellular carcinoma: Is the jury still out?Surgical Oncology, 2009
- Evaluation of tumor response after locoregional therapies in hepatocellular carcinomaCancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Guidelines for imaging focal lesions in liver cirrhosisExpert Review of Gastroenterology & Hepatology, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?The Oncologist, 2006